SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Organon investigation or if you are an Organon investor who suffered a loss and would like to learn more, you can prov ...

Take advantage of the currently offered discount on annual memberships and give CIP a try. The offer comes with an 11-month money guarantee , for first time members.Conservative Income Portfolio targets the best value stocks with the highest margins of safety. The volatility of these investments is further lowered using the best priced options. Our Enhanced Equity Income Solutions Portfolio is designed to reduce volatility while generating 7-9% yields.While we have not written specifically about Organon (NY ...

Sales Performance - Worldwide sales for the three months ended March 31, 2025, were $1.5 billion, a decrease of 7% compared to 2024, negatively impacted by approximately 3% or $44 million due to unfavorable foreign exchange rates [98]. - Sales in the United States increased by 11% to $412 million for the three months ended March 31, 2025, compared to $371 million in 2024 [98]. - International sales decreased by 12% to $1.1 billion for the three months ended March 31, 2025, compared to $1.25 billion in 2024 [98]. - Nexplanon sales increased by 13% to $248 million for the three months ended March 31, 2025, driven by increased demand and favorable pricing in the United States [102][103]. - NuvaRing sales declined by 43% to $22 million for the three months ended March 31, 2025, due to ongoing generic competition and increased government discount rates in the United States [104]. - Follistim AQ sales increased by 49% to $69 million for the three months ended March 31, 2025, due to a one-time buy-in and favorable discount rates in the United States [106]. - Hadlima sales reached $47 million during the three months ended March 31, 2025, reflecting continued ramp-up since its July 2023 launch in the United States [108][109]. - Atozet's loss of exclusivity negatively impacted sales by approximately $63 million during the three months ended March 31, 2025 [99]. - Ontruzant sales declined 54% to normalized levels in Brazil and lower demand in the U.S. for the three months ended March 31, 2025 [110]. - Brenzys sales decreased 39% due to the timing of international tenders in Brazil for the same period [110]. - Atozet sales fell 42% primarily due to loss of exclusivity in France and Spain, with expectations of continued decline in 2025 [112]. - Combined sales of Zetia and Vytorin decreased 4%, driven by demand decrease and pricing pressure in international markets [113]. - Cozaar and Hyzaar sales declined 18% due to decreased demand in China and Japan, along with mandatory price reductions in Japan [114]. - Singulair sales decreased 24% due to lower respiratory infections in China and reduced demand in Japan [115]. Financial Overview - Gross profit decreased 12% to $841 million for the three months ended March 31, 2025, impacted by unfavorable pricing and decreased sales [120]. - Research and development expenses decreased 14% to $96 million, primarily due to reduced clinical study activity [124]. - Restructuring costs increased to $86 million, with expected annual savings of approximately $200 million from cost-saving initiatives [126]. - Cash and cash equivalents as of March 31, 2025, were $547 million, with working capital increasing to $1.76 billion [131][132]. Market and Risk Management - No changes to market risk were reported for the quarter ended March 31, 2025 [142]. - For detailed market risk exposure, refer to the Annual Report on Form 10-K for the year ended December 31, 2024 [142]. - Recently issued accounting standards are discussed in Note 2 of the Condensed Consolidated Financial Statements [141]. Corporate Developments - The acquisition of Tofidence from Biogen includes an upfront payment of $51 million and potential milestone payments of up to $45 million based on net sales [96].

Organon (OGN) reported $1.51 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 6.7%. EPS of $1.02 for the same period compares to $1.22 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.52 billion, representing a surprise of -0.73%. The company delivered an EPS surprise of +14.61%, with the consensus EPS estimate being $0.89.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

Organon (OGN) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $1.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.61%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.86 per share when it actually produced earnings of $0.90, delivering a surprise of 4.65%.Over the last four quarters, the com ...

Organon First Quarter 2025 Earnings Disclaimer statement Cautionary Note Regarding Forward-Looking Statements Except for historical information, this presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management's expectations about Organon's future financial performance and prospects, including expectations regarding regulatory approvals (including t ...

Organon (OGN) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Company Participants Jennifer Halchak - VP, IRKevin Ali - CEOMatthew Walsh - CFOMichael Nedelcovych - Director - Equity ResearchUmer Raffat - Senior Managing DirectorJuan Camilo Ferreira - Executive VP, Head of Research & Development and Chief Medical Officer Conference Call Participants David Amsellem - Sr. Research AnalystEthan Brown - Equity Research AnalystBhavin Patel - Analyst Operator Hello, and welcome to the Organon First Quarter twenty t ...

Organon (OGN) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Speaker0 Hello, and welcome to the Organon First Quarter twenty twenty five Earnings Call and Webcast. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I would now like to turn the conference over to Jennifer Halczek, Vice President, Investor Relations. You may begin. Speaker1 Thank you, operator, and good morning, everyone. Thank you for joining Organon's ...

Exhibit 99.1 (614) 314-8094 Kate Vossen (732) 675-8448 Media Contacts: Karissa Peer Investor Contacts: Jennifer Halchak (201) 275-2711 Renee McKnight (551) 204-6129 Organon Reports Results for the First Quarter Ended March 31, 2025 Company af irms full year 2025 financial guidance, resets dividend payout to strengthen capital structure 1 · Guidance ranges for full year 2025 revenue and Adjusted EBITDA margin are affirmed; company expects to generate over $900 million of free cash flow before one-time costs ...

Organon (OGN) closed at $12.20 in the latest trading session, marking a +0.66% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.74%. Elsewhere, the Dow gained 0.05%, while the tech-heavy Nasdaq added 1.26%.The pharmaceutical company's shares have seen a decrease of 16.76% over the last month, not keeping up with the Medical sector's loss of 7.7% and the S&P 500's loss of 4.77%.Investors will be eagerly watching for the performance of Organon in its upcoming earnings ...